From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Participants were randomly assigned to receive weekly injections of retatrutide at doses of 1 mg, 4 mg, 8 mg or 12 mg, or a placebo for 48 weeks
Q3: What are the side effects of tesamorelin
But no need to flip out
It's a formidable cycle
It is typically prescribed for people who have found it difficult to lose weight through diet and exercise alone, particularly where excess weight is affecting overall health or increasing the risk of future health conditions
